Therefore, targeting of BCL-2-like proteins is an interesting option in anticancer therapy [68,79,80], and our study points to the involvement of MCL-1, especially in MITFhigh populations, in phenotypic plasticity of melanoma cells used in immediate adaptation to modifications of the microenvironment. This evidence concerns the gene MCL1 and melanoma.